Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04134559 · ClinicalTrials.gov registry record · Phase 2

Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma

A Phase 2 study of Liver Cancer and Fibrolamellar Carcinoma, sponsored by Allison O'Neill, MD.

Recruiting
Registry status
Phase 2
Development phase
18
Enrollment target
5
Study locations

NCT04134559 is a Phase 2 study of Liver Cancer and Fibrolamellar Carcinoma that is actively recruiting participants, run by Allison O'Neill, MD. The registered enrollment target is 18 participants, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04134559, a Phase 2 study of Liver Cancer and Fibrolamellar Carcinoma, is actively recruiting participants, sponsored by Allison O'Neill, MD.

RECRUITING
Registry status
Phase 2
Development phase
18 participants
Enrollment target
5
Study locations

Study Summary

This research study is studying an immunotherapy drug (pembrolizumab or KEYTRUDA) as a possible treatment for pediatric hepatocellular carcinoma or hepatocellular neoplasm not otherwise specified (HCN NOS).

Conditions Studied

Liver Cancer Fibrolamellar Carcinoma Hepatocellular Carcinoma, Childhood Liver Cancer, Pediatric

Interventions

  • DRUG Pembrolizumab

Study Locations (5)

Massachusetts

  • Children's Hospital Boston - Boston
  • Dana Farber Cancer Institute - Boston

California

  • University of California San Francisco - San Francisco

Ohio

  • Cincinnati Children's Medical Center - Cincinnati

Texas

  • Baylor College of Medicine - Houston

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2020-11-01
Est. Completion 2028-01-01
Phase Phase 2

Sponsor

Allison O'Neill, MD

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04134559

The ClinicalTrials.gov registry entry for NCT04134559 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Allison O'Neill, MD, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.

NCT04134559 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, California, Ohio.

Frequently Asked Questions

What is clinical trial NCT04134559 about?

NCT04134559 is a clinical study titled "Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma". This research study is studying an immunotherapy drug (pembrolizumab or KEYTRUDA) as a possible treatment for pediatric hepatocellular carcinoma or hepatocellular neoplasm not otherwise specified (HCN NOS).

What is the current status of trial NCT04134559?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2020-11-01. Estimated completion is 2028-01-01.

What conditions does trial NCT04134559 study?

This clinical trial studies the following conditions: Liver Cancer, Fibrolamellar Carcinoma, Hepatocellular Carcinoma, Childhood, Liver Cancer, Pediatric.

What interventions are being tested in trial NCT04134559?

The interventions under investigation include: Pembrolizumab (DRUG).

Who is sponsoring clinical trial NCT04134559?

This trial is sponsored by Allison O'Neill, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04134559 being conducted?

This trial has 5 study locations across California, Massachusetts, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Liver Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Liver Cancer

All registered trials for this condition

Fibrolamellar Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.